Explore

Trendline Trendline
Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026

Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026

Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026
Trendline Trendline
Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase
Trendline Trendline
Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion

Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion

Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion
Trendline Trendline
NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials

NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials

NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials
Trendline Trendline
Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress

Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress

Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress
Trendline Trendline
NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements

NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements

NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements
Trendline Trendline
Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials

Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials

Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials
Trendline Trendline
Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements
Trendline Trendline
BrainStorm Cell Therapeutics Prepares for Phase 3 ALS Study Amid Financial Challenges

BrainStorm Cell Therapeutics Prepares for Phase 3 ALS Study Amid Financial Challenges

BrainStorm Cell Therapeutics Prepares for Phase 3 ALS Study Amid Financial Challenges
Trendline Trendline
Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates

Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates

Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates
Trendline Trendline
Immunome Submits NDA for Varegacestat and Reports Financial Results

Immunome Submits NDA for Varegacestat and Reports Financial Results

Immunome Submits NDA for Varegacestat and Reports Financial Results
Trendline Trendline
Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress

Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress

Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress